The Selling of Attention Deficit Disorder
The Selling of Attention Deficit Disorder
This article from The New York Times investigates the rising rates of diagnosis and medication for Attention Deficit Hyperactivity Disorder (ADHD) in America. It explores the complex factors behind the surge, including pharmaceutical marketing, increased awareness, and changes in diagnostic criteria. The article highlights the influence of drug companies in promoting and expanding the definition of ADHD, leading to concerns about overdiagnosis and overmedication. It also discusses the potential consequences and ethical implications of pathologizing normal childhood behaviors. Overall, the article delves into the commercialization of ADHD and its impact on the mental health industry.
Note
this record does not have a note
Summary
This article from The New York Times investigates the rising rates of diagnosis and medication for Attention Deficit Hyperactivity Disorder (ADHD) in America. It explores the complex factors behind the surge, including pharmaceutical marketing, increased awareness, and changes in diagnostic criteria. The article highlights the influence of drug companies in promoting and expanding the definition of ADHD, leading to concerns about overdiagnosis and overmedication. It also discusses the potential consequences and ethical implications of pathologizing normal childhood behaviors. Overall, the article delves into the commercialization of ADHD and its impact on the mental health industry.
Image
